Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
801-820 of 1,743 trials

Advanced Non-Hodgkin’s Lymphoma: ARV-393 Study

We are evaluating a new treatment called ARV-393 for adults with advanced Non-Hodgkin’s Lymphoma. The goal is to see how well it works and its safety compared to current options.

Advanced Non-Hodgkin’s Lymphoma>2 yearsSafety phase (I)Oncology

Sufentanil for Pain Management in Abdominal Surgery

We are studying how the use of sufentanil during non-major abdominal surgery affects long-term pain and recovery. This trial looks at both immediate and chronic pain experiences in patients.

Chronic Postsurgical Pain>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Chronic Lymphocytic Leukemia: Acalabrutinib Treatment Study

We are investigating whether acalabrutinib is safe and effective for adults with chronic lymphocytic leukemia and heart problems. This study compares it to other treatment options available for these patients.

Chronic Lymphocytic Leukaemia with Cardiac Impairment>2 yearsMonitoring phase (IV)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyHematology

Myelodysplastic Syndromes: Ivosidenib vs. Azacitidine

We are studying the effects of a new drug, ivosidenib, in adults with myelodysplastic syndromes who have an IDH1 mutation. The goal is to understand its effectiveness and safety compared to azacitidine.

Myelodysplastic Syndrome (MDS)Hypomethylating Agent Naive Myelodysplastic Syndromes>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Long-Term Study of Galapagos CAR T-Cell Therapies

We are evaluating the long-term safety and effectiveness of Galapagos CAR T-cell therapies in patients. This study aims to understand how these treatments work over many years.

Relapsed/Refractory B-Cell Non-Hodgkin LymphomaRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Acute Agitation: Comparing New Medications

We are studying how well sublingual dexmedetomidine and buccal midazolam work for calming patients in emergency settings compared to oral lorazepam. We also want to know about their safety and how satisfied patients feel with these treatments.

Acute Agitation>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPsychiatry

GSDIa: DTX401 Treatment Study

We are examining the long-term safety and pregnancy outcomes of DTX401 for individuals with GSDIa. This study will help us understand how effective this treatment is over time.

Glycogen Storage Disease Type IA>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Multiple Sclerosis: Stem Cell Treatment Study

We are investigating whether a new stem cell treatment can help regenerate nerve function in patients with progressive multiple sclerosis. The study will also assess safety and other health measures.

Multiple Sclerosis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

Rare Cancers: Dendritic Cell Vaccine Study

We are testing a new vaccine made from patients' own tumor cells for those with resected stage IV neuroendocrine tumors and soft tissue sarcomas. The study aims to evaluate safety and how well the immune system responds to the treatment.

Soft Tissue SarcomaNeuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Behçet's Syndrome: Steroids Plus Anticoagulants Study

We are investigating whether adding anticoagulants to steroid therapy helps reduce the risk of deep venous thrombosis relapse in people with Behçet's syndrome. This study will also look at safety and quality of life.

Behcet's Syndrome>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesHematologyInternal MedicineRheumatology

Oral Midazolam for Patients Refusing Care

We are studying whether oral midazolam can help older patients with moderate to severe cognitive disorders accept necessary care. The trial also looks at its safety and the satisfaction of healthcare providers.

Cognitive Issues and Agitation in the Elderly>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyPsychiatry

Urinary Incontinence in Children: StayDry Study

We are exploring how stopping medication for urinary incontinence affects recurrence and overall well-being in children. The study compares abrupt versus gradual withdrawal of treatments like solifenacin and mirabegron.

Daytime Urinary Incontinence>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesUrology

Acute Myeloid Leukemia: Ziftomenib Combinations

We are investigating the safety and tolerability of Ziftomenib in patients with relapsed or refractory acute myeloid leukemia. This study aims to understand how well this treatment works alongside other therapies.

Relapsed Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Chronic Lymphocytic Leukemia: Venetoclax and Pirtobrutinib Study

We are comparing different treatment plans for newly diagnosed chronic lymphocytic leukemia patients to see if a personalized approach improves outcomes. This includes assessing how long patients can stay in remission and the overall effectiveness of the treatments.

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Acute Myeloid Leukemia: Multi-Peptide Vaccine Study

We are testing a new vaccine to see if it helps AML patients who are in complete remission after their first treatment. The goal is to improve their chances of staying in remission.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Head and Neck Cancer: Petosemtamab Treatment Study

We are studying the effects of petosemtamab in patients with advanced head and neck cancer who have not responded to previous treatments. The goal is to see if it improves survival and tumor response compared to standard therapies.

Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Head and Neck Cancer: Petosemtamab with Pembrolizumab

We are studying a new treatment combination for patients with recurrent or metastatic head and neck cancer to see if it works better than standard treatment. This trial is for those with tumors that express PD-L1.

Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Paroxysmal Nocturnal Hemoglobinuria: Pozelimab and Cemdisiran Therapy

We are studying the long-term safety and effectiveness of a combination therapy for adults with Paroxysmal Nocturnal Hemoglobinuria. This trial will help us understand its impact on symptoms like fatigue and hemoglobin levels.

Paroxysmal Nocturnal Hemoglobinuria>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Myotonic Dystrophy Type 1: DYNE-101 Treatment Study

We are evaluating the safety and effects of a new treatment, DYNE-101, for people with Myotonic Dystrophy Type 1. The study aims to see how it impacts muscle health and overall well-being.

Myotonic Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyOrthopedics and Traumatology

Pancreatic, Lung, Breast, and Colorectal Cancers: [177Lu]Lu-NNS309

We are evaluating a new treatment for patients with pancreatic, lung, breast, and colorectal cancers. The study aims to assess its safety and how well it works in these cancer types.

Non-Small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)>2 yearsSafety phase (I)Oncology